Indo US Bio-Tech Limited has scheduled its 22nd Annual General Meeting (AGM) for September 30, 2026. The meeting will address the appointment of statutory auditors, the reappointment of a retiring director, and significant special business items including enhanced borrowing limits and related-party transaction approvals.

The Board of Directors approved the draft notice and Directors' Report in its meeting held on September 5, 2026. The AGM will be conducted through Video Conferencing (VC) or Other Audio-Visual Means (OAVM) at 2:30 pm.

Auditor Appointment and Director Reappointment

The Board recommended appointing M/s. Bhagat & Associates, Chartered Accountants (FRN: 101100W), as Statutory Auditors for a period of five consecutive years. This term runs from the conclusion of the 22nd AGM until the conclusion of the 27th AGM, subject to shareholder approval.

Additionally, shareholders will vote on the reappointment of Mrs. Priyanka Samarth Patel (DIN: 07941023) as a Director. She retires by rotation at this meeting and is eligible for reappointment.

Special Business: Borrowing and Related Parties

The AGM agenda includes two special resolutions:

1. Borrowing Limits: Shareholders will decide on empowering the Board to borrow up to ₹250 crore over and above the aggregate of paid-up capital, free reserves, and securities premium. The resolution also permits creating charges on company assets up to ₹100 crore.
2. Related Party Transactions: Approval is sought for transactions with related parties under Section 188 of the Companies Act, 2013, with an annual limit of ₹10 crore for each type of transaction.

Disclosures for FY26 show various related-party dealings, including advances given to Indo US Agriseeds Limited (₹3.45 crore) and Patel Beej Nigam (₹1.20 crore). Loans taken from promoter Jagdish D. Ajudia amounted to ₹11 lakh, while repayments totaled ₹11.60 lakh.

AGM Logistics and Voting

Shareholders holding shares on the record date of September 23, 2026, are eligible to vote. The remote e-voting period runs from September 27, 2026, at 9:00 am to September 29, 2026, at 5:00 pm. M/s. Amrish Gandhi & Associates will scrutinize the e-voting process.

The book closure for equity shares is from September 23, 2026, to September 30, 2026, inclusive, in compliance with Regulation 42 of the SEBI (LODR) Regulations 2015.

Indo US Bio-Tech Limited reported a net profit of ₹3.04 crore for the quarter ended June 30, 2026, a 35% decrease from ₹4.70 crore in the corresponding quarter of FY26. Revenue from operations grew 7% year-on-year to ₹32.99 crore, driven by steady demand in its seed cultivation, processing, and trading segment. The improvement in profitability was primarily aided by a significant reduction in employee benefit expenses, which turned negative in the prior year due to reversals, stabilizing operational costs in the current period.

The Board of Directors, at a meeting held on August 12, 2026, approved the unaudited standalone financial results pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and received a limited review report from Bhagat & Associates, the statutory auditors, who expressed an unmodified opinion on the financial statements.

Financial Performance Highlights

*Note: Total expenses calculation includes Purchase of stock (₹524.19 lakh), Production Expenses (₹862.55 lakh), Employee Benefits (₹1,215.96 lakh), Finance Costs (₹32.94 lakh), Depreciation (₹73.93 lakh), and Other Expenses (₹26.89 lakh). The source table lists "Total Expenses" as ₹266.90 lakh before a subsequent line item of ₹3,003.35 lakh, which aligns with the sum of individual expense categories minus the negative impact of inventory changes or specific accounting adjustments not explicitly detailed in the summary rows. The profit before tax is derived as Total Income (₹3,311.05 lakh) less Total Expenses (₹3,003.35 lakh).

Revenue from operations stood at ₹3,298.68 lakh, compared to ₹3,076.96 lakh in Q1FY26. Other income increased significantly to ₹12.38 lakh from ₹0.15 lakh in the prior year. Production expenses rose to ₹862.55 lakh from ₹883.95 lakh in the same quarter last year, indicating stable cost management in core activities. However, employee benefit expenses recorded at ₹1,215.96 lakh contrasted with a credit of ₹(1,907.58) lakh in Q1FY26, reflecting a normalization of costs after prior-period adjustments.

What the Numbers Show

The divergence between revenue growth and profit decline highlights the impact of one-time items in the previous year. While revenue expanded by 7%, the profit before tax fell 36% because Q1FY26 benefited from a substantial reversal in employee benefits (₹1,907.58 lakh credit), whereas Q1FY27 incurred standard charges of ₹1,215.96 lakh. Excluding this anomaly, the underlying operational structure remains consistent, with production costs remaining relatively flat against higher sales volumes. The company continues to operate in a single major segment: Seed Cultivation, Processing & Trading.

The Board meeting commenced at 14:30 and concluded at 15:10 on August 12, 2026. There were no investor complaints pending or received during the period under review. The financial results have been prepared in accordance with Ind-AS 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013.